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Abstract
Objective: To investigate whether IGF-I promoter polymorphism was associated with birth weight
and risk factors for cardiovascular disease (CVD) and type 2 diabetes (T2DM), and whether the
birth weight – risk factor relationship was the same for each genotype.
Design and participants: 264 subjects (mean age 36 years) had data available on birth weight,
IGF-I promoter polymorphism genotype, CVD and T2DM risk factors. Student's t-test and
regression analyses were applied to analyse differences in birth weight and differences in the birth
weight – risk factors relationship between the genotypes.
Results: Male variant carriers (VCs) of the IGF-I promoter polymorphism had a 0.2 kg lower birth
weight than men with the wild type allele (p = 0.009). Of the risk factors for CVD and T2DM, solely
LDL concentration was associated with the genotype for the polymorphism. Most birth weight –
risk factor relationships were stronger in the VC subjects; among others the birth weight – systolic
blood pressure relationship: 1 kg lower birth weight was related to an 8.0 mmHg higher systolic
blood pressure
Conclusion: The polymorphism in the promoter region of the IGF-I gene is related to birth weight
in men only, and to LDL concentration only. Furthermore, the genotype for this polymorphism
modified the relationships between birth weight and the risk factors, especially for systolic and
diastolic blood pressure.
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Insulin-like growth factor-1 (IGF-I) is a peptide that is
involved in fetal growth and cell differentiation [1,2] In
addition, it has been suggested that this peptide plays a
role in the regulation of glucose homeostasis and cardio-
vascular function [3-6] (Lower IGF-I levels are also associ-
ated with increased levels of serum low-density
lipoprotein (LDL) [7]. IGF-I also plays a role in plaque
development [8].
A genetic polymorphism comprising a variable length
cytosine-adenine (CA) repeat sequence in the promoter
region of the IGF-I gene has been identified, and is
thought to influence the transcription rate of IGF-I, which
in turn affects serum IGF-I levels [9]. Since IGF-levels are
associated with fetal growth and adult risks for cardiovas-
cular disease (CVD) and type 2 diabetes (T2DM), it has
been suggested that the polymorphism in the promoter
region of the IGF-I gene might be relevant to the fetal ori-
gins hypothesis. This hypothesis suggests that an adverse
environment during the intra-uterine period negatively
affects fetal growth (often estimated by birth weight), and
results in adaptations that permanently change the struc-
ture and functions of the body, which leads to an
increased risk for disease, such as CVD and T2DM, at adult
age [10]. An alternative hypothesis is that impaired fetal
growth and increased risk for CVD and T2DM share a
common genetic factor [11,12] A study performed in Rot-
terdam in the Netherlands has recently shown that the
absence of the wild type allele (192 base pair (bp)) in the
promoter region IGF-I gene was related to lower birth
weight [13]. In addition, the intra-uterine environment
may interact with genetic polymorphisms [14]. This has
already been found in other studies, two of which con-
cerned on birth weight and genetic factors in insulin
metabolism [15-17] These data raise the issue of whether
or not birth weight also interacts with the IGF-I gene.
In the Amsterdam Growth and Health Longitudinal Study
(AGAHLS), data on birth weight, and risk factors for CVD
and T2DM have been collected. The IGF-I gene has now
been analysed for the 192 bp polymorphism [9,13], in
order to address the following four research questions: 1)
Is the IGF-I promoter polymorphism genotype associated
with birth weight? 2) Is IGF-I promoter polymorphism gen-
otype associated with risk factors for CVD and T2DM? 3)
Is birth weight associated with risk factors for CVD and
T2DM and finally 4) Do intra-uterine environment and
the IGF-I promoter polymorphism genotype interact? Or,
in other words, is the association between birth weight
and risk factors for CVD and T2DM different for each gen-
otype of this polymorphism?
Methods
Participants
The Dutch population described in this study are all par-
ticipants of the AGAHLS. The AGAHLS is an observational
study with repeated measurements, which started in 1976
to monitor boys and girls with a mean age of 13 years
[18]. During the most recent measurement in which 433
subjects participated, subjects had than reached a mean
age of 36 years, information was obtained concerning
birth weight, IGF-I promoter polymorphism genotype, gly-
cated hemoglobin (HbA1c), carotid intima-media thick-
ness (IMT), blood pressure, anthropometry and serum
low density lipoprotein (LDL) cholesterol levels. Three-
hundred-ninety-one subjects completed the birth-weight
questionnaire of whom 380 had written information or
information from parents. For the purpose of the present
study, subjects who were born pre-term (before 37 weeks
of gestation, 27 subjects), were one of a twin (11 subjects)
or were of non-Caucasian ethnicity (9 subjects) were
excluded. Another 69 subjects were not taken into account
for the analyses because of errors or missing values in the
genotyping or risk factor measurements. Finally, for 264
subjects (152 women) there were complete data sets on
the IGF-I promoter polymorphism genotype, birth weight,
and adult risk factors for CVD and T2DM. Subjects
included for the analyses were smaller (1.76 m vs. 1.77 m,
p = 0.030) and had less fat-free mass (56.5 kg vs. 57.9 kg,
p = 0.056) compared to subjects not included for these
analyses, but with data on the outcomes available (N =
109). On all other outcome variables the groups did not
differ. (Some outcome measures had missing values,
which were due to error in the specific measurement.) All
subjects were apparently healthy at the time of the meas-
urements, and none had been diagnosed with T2DM. All
subjects gave written informed consent and the Medical
Ethical Committee of the VU University Medical Center
approved the protocol.
Birth weight
Data on birth weight were obtained by means of a ques-
tionnaire. The questions concerned birth weight, gesta-
tional age, being one of a twin, and ethnicity, and subjects
were also asked about the source of the information. Only
those who had received the information from their par-
ents or had it in written documents were included, as this
has been shown to be a valid method [19,20] Subjects
born preterm (gestational age < 37 weeks) were excluded,
this may have independent effects on adult health or
influence the relationship between birth weight and adult
health [21-23]. Twins were excluded because they have
different fetal growth patterns, which might cause error
when analysing the relationship between birth weight and
adult health outcomes. Subjects who retrieved the birth
weight information from their parents' memory (n = 112)
had slightly higher mean birth weights (3.54 ± 0.53 kg)Page 2 of 9
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information from written documents (n = 152; 3.44 ±
0.48 kg), but this difference was not significant (p = 0.10).
Furthermore, they did not differ significantly on any of
the outcome measures.
Polymorphism in the promoter region of the IGF-I gene
IGF-I promoter polymorphism genotypes were determined
as described earlier [9]. In brief, DNA was isolated using
standard methods. PCR was performed in a final volume
of 10 µL containing 10 ng DNA, 10* Gold (Au) buffer
(Perkins and Elmer), 200 M dNTP, 30 pmol of each
primer, 3 mM MgCl2, 0.5 U Ampli Tag Gold polymerase
(Perkins and Elmer). The PCR program concisted of 30
cycli of 30 sec 95°C, 30 sec 55°C and 30 sec 72°C and
additionally 5 min of denaturation at 95°C before the
first cycle and an extension of 10 min. at 72°C after the
last cycle. Forward primers were labelled with FAM
(Weber & May 1989) to determine the size of the PCR
products by fragment analysis (ABI-Prism genetic analyser
with Genescan 2.1 software). The Genescan 350/500
Tamra was used as internal size standard within the frag-
ment analysis.
Rietveld et al[24] recently demonstrated that subjects who
were homozygous for the 192 bp or the 194 bp allele had
comparable IGF-I blood levels, while individuals who
were homozygous for either alleles shorter than 192 bp or
longer than 194 bp had significantly lower serum IGF-I
levels. Therefore, we decided to regard all subjects who
were homozygous for 192 bp or 194 bp, or were carrier of
a 192 bp allele and a 194 bp allele as wild types (WTs).
Consequently, all subjects who were carrier of a variant
allele, which is either shorter than 192 bp or longer than
194 bp, were grouped as variant carriers (VCs).
Risk factors for CVD and T2DM
The following risk factors for CVD and T2DM were meas-
ured: body mass index (BMI), waist circumference, waist-
to-hip ratio (WHR), total fat mass (FM), total fat-free mass
(FFM), carotid intima-media thickness (IMT), systolic and
diastolic blood pressure (SBP, DBP), resting heart rate,
LDL cholesterol levels and HbA1c as an estimate of glucose
metabolism (unfortunately no glucose measures were
available). BMI was calculated as body weight (kg)
divided by body height (m2). Standing height was meas-
ured with a stadiometer to the nearest 0.001 m. Body
weight (kg) was measured to the nearest 0.1 kg using a
spring balance scale (Van Vucht, Amsterdam, The Nether-
lands), with subjects dressed only in underwear. Waist (at
the level of the umbilicus) and hip circumference were
measured with a flexible steel tape to the nearest 0.1 cm.
WHR was calculated as the ratio between waist circumfer-
ence and hip circumference. Fat mass (FM) was estimated
from four skinfolds (biceps, triceps, subscapular and
supra iliacal) with the Durnin and Womersley equation
[25]. The four skinfolds were measured according to
standard procedures [26]. FFM was calculated by subtract-
ing FM from body weight.
IMT of the right common carotid artery was obtained by
an ultrasound scanner equipped with a 7.5 MHz linear
array probe (Pie Medical, Maastricht, The Netherlands), as
described elsewhere in more detail [27-29] SBP and DBP
were assessed in the left arm at 5-minute intervals with an
oscillometric device (Colin Press-Mate, model BP 8800,
Komaki-City, Japan) during the entire period of ultra-
sound imaging when the subjects were lying in a supine
position. The mean value over this entire period was cal-
culated. Resting heart rate was measured with the same
device as used for the blood pressure measurement. The
mean value over this measurement period was calculated
and used in the analyses.
Serum LDL and HbA1c (%) were measured from blood
samples (10 ml) taken from the antecubital vein between
8.30 and 12.30 a.m. with subjects in a non-fasting state.
Standard methods were used to analyse the LDL concen-
tration and external quality control took place with target
samples from a World Health Organisation reference lab-
oratory (Lipid Standardization Laboratory, Atlanta, USA).
HbA1c was determined by non-exchange high perform-
ance liquid chromatography with a modular Diabetes
Monitoring System (Bio-Rad, Veenendaal, the
Netherlands).
Data-analyses
A t-test was used to analyse differences in birth weight
between the IGF-I promoter polymorphism genotypes.
Multiple linear regression analyses were applied to study
the associations between birth weight and the risk factors
for CVD and T2DM. The results of the regression analyses
were presented as regression coefficients (β) and the cor-
responding 95% confidence intervals (CI) for two differ-
ent models. The first model was a crude analysis, only
adjusted for gender (and for SBP and DBP in case of IMT).
The second was further adjusted for adult body weight.
To investigate whether the relationship between birth
weight and the risk factors for CVD and T2DM were mod-
ified by the IGF-I promoter polymorphism, multiple linear
regression was performed between birth weight and all
risk factors (all as continuous variables) for the two geno-
types separately.
All analyses were performed with the Statistical Package of
Social Science (SPSS, Chicago, USA) version 10.1. The sta-
tistical significance was set at p-value ≤ 0.05.Page 3 of 9
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Table 1 gives allele and genotype frequencies in this
cohort. As can be seen, of all 264 subjects, 189 (111
women) were WTs for the IGF-I promoter polymorphism.
The remaining 75 subjects (41 women), 4 were
homozygous for alleles with variant CA repeats and 71
were heterozygous for variant alleles. The distribution of
genotypes was in Hardy-Weinberg equilibrium (p = 0.17).
Population characteristics on all measured variables are
presented in Table 2, stratified according to gender and
genotype. In men, the mean birth weight was 0.2 kg lower
in the VC group than in the WT group (p = 0.009). In
women, no significant differences in birth weights
between the genotypes were observed (p = 0.755).
Subjects in the VC group had significantly higher LDL
concentrations (p = 0.039). No other significant differ-
ences between the genotypes were observed.
Table 3 presents the results of the linear regression analy-
ses for the relationship between birth weight and risk fac-
tors for CVD and T2DM. It was found that 1 kg higher
birth weight was associated with 2.55 kg more FFM. How-
ever, this association decreased and lost significance after
adjustment for adult body weight. In addition, birth
weight was found to be associated with SBP in such a way
that 1 kg lower birth weight was related to a 3.05 mmHg
higher SBP. No other significant associations were
observed between birth weight and risk factors for CVD
and T2DM.
Table 1: Allelic and genotype frequencies for the bp repeat polymorphism at the promoter region of the IGF-I gene
Allele (bp length) Frequency N (%) Genotype Frequency N (%)
176 3 (0.5) WT 192/192 105 (39.8)
188 10 (1.9) 192/194 78 (29.5)
190 23 (4.4) 194/194 6 (2.3)
192 341 (64.6) total 189 (71.6)
194 108 (20.5) VC 192/x 53 (20.0)
196 38 (7.2) 194/x 18 (6.8)
198 5 (1.0) x/x 4 (1.5)
total 75 (28.4)
X, alleles with bp lengths other than 192 or 194; WT, Wild Type; VC, Variant Carrier
Table 2: Characteristics of the adult population of the Amsterdam Growth and Health Longitudinal Study
Men Women
WT VC WT VC
Mean ± SD Mean ± SD Mean ± SD Mean ± SD
Birth weight (kg) 3.64 ± 0.47 3.40 ± 0.39 3.44 ± 0.53 3.41 ± 0.52
Height (m) 1.84 ± 0.08 1.83 ± 0.07 1.71 ± 0.06 1.72 ± 0.06
Weight (kg) 84.1 ± 10.8 85.2 ± 10.8 67.5 ± 9.3 69.2 ± 11.8
Body mass index (kg/m2) 23.5 ± 2.6 24.5 ± 2.4 22.4 ± 2.9 22.8 ± 3.8
Fat-mass (kg) 13.7 ± 5.0 15.3 ± 5.6 17.7 ± 5.3 18.4 ± 6.4
Fat-free mass (kg) 66.1 ± 6.6 66.3 ± 5.7 47.3 ± 4.5 48.7 ± 5.9
Waist circumference (cm) 85.3 ± 7.5 85.9 ± 8.8 73.3 ± 8.9 73.4 ± 8.0
Waist-to-hip ratio 0.95 ± 0.04 0.96 ± 0.05 0.83 ± 0.08 0.82 ± 0.08
Systolic blood pressure (mmHg) 121.0 ± 8.9 122.7 ± 14.4 110.7 ± 10.6 111.8 ± 12.0
Diastolic blood pressure (mmHg) 66.4 ± 6.4 67.2 ± 8.6 63.1 ± 7.2 61.6 ± 6.9
LDL concentration (mmol/l) 3.22 ± 0.80 3.52 ± 0.87 2.80 ± 0.81 2.97 ± 0.70
Carotid intima-media thickness (mm) 0.628 ± 0.099 0.636 ± 0.095 0.616 ± 0.086 0.631 ± 0.101
Resting heart rate (b/min) 73 ± 12 69 ± 11 72 ± 12 70 ± 12
Glycated hemoglobin (%) 5.3 ± 0.5 5.3 ± 0.3 5.3 ± 0.4 5.3 ± 0.3
Data is presented as means ± standard deviations (SD),
†WT, Wild type; VC, Variant carrier LDL – low lipoproteinPage 4 of 9
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between birth weight and the risk factors for CVD and
T2DM, stratified according to IGF-I promoter polymor-
phism genotypes. In most of the associations studied, the
regression coefficient for birth weight was highest in the
VC group, indicating a stronger effect of birth weight on
the outcome variable. This difference was most marked in
the association with SBP, in which a 1 kg lower birth
weight was related to an 8.0 mmHg increase in adult SBP
in the VC group, compared to a 1.4 mmHg increase in the
WT group. Although, the difference between the VC group
and WT group was not statistically significant (p = 0.08)
for these kind of 'interactions' normally a higher signifi-
cance level is used. In addition, the relationships between
birth weight and DBP and FM were significant in the VC
group and not in the WT group (p = 0.06 for the difference
between VCs and WTs for DBP). The differences between
VCs and WTs regarding all other relationships showed p-
values > 0.10.
For the associations between birth weight and adult FFM,
waist circumference, LDL and resting heart rate, the regres-
Table 3: Results of the linear regression analyses for the relationship between birth weight and adult risk factors for CVD and DM-2
Crude† Adjusted ‡
Outcome β 95%CI β 95%CI
Body mass index (kg/m2) 0.445 [-0.264; 1.154]
Fat-mass (kg) 0.962 [-0.361; 2.285] -0.663 [-1.605; 0.208]
Fat-free mass (kg) 2.553*** [1.224; 3.882] 0.714 [-0.085; 1.513]
Waist circumference (cm) 1.760 [-0.372; 3.892] -1.013 [-2.253; 0.227]
Waist-to-hip ratio 0.012 [-0.005; 0.028] 0.006 [-0.011; 0.022]
Systolic blood pressure (mmHg) -1.387 [-4.082; 1.309] -3.050* [-5.626; -0.475]
Diastolic blood pressure (mmHg) -0.692 [-2.445; 1.071] -1.608 [-3.329; 0.113]
Resting heart rate (b/min) 1.941 [-0.932; 4.815] 1.861 [-1.081; 4.803]
Low density lipoprotein (mmol/l) -0.079 [-0.277; 0.118] -0.154 [-0.351; 0.044]
Carotid intima-media thickness (mm) || 0.011 [-0.012; 0.034] 0.011 [-0.012; 0.035]
Glycated hemoglobin (%) -0.013 [-0.109; 0.082] -0.025 [-0.123; 0.072]
Data is presented as regression coefficients and corresponding 95% confidence intervals (CI)
CVD – cardiovascular disease; DM-2 – type 2 diabetes mellitus
† Crude, only adjusted for gender; ‡, Adjusted, further adjusted for adult body weight
* p < 0.05 *** p < 0.001
|| also adjusted for systolic and diastolic blood pressure
Table 4: Analyses stratified according to genotype for the relationship between birth weight and risk factors for CVD and DM-2
Wild type Variant carrier
Risk factor β 95% CI β 95% CI
BMI (kg/m2) 0.475 [-0.312; 1.262] 0.777 [-0.835; 2.338]
Fat mass (kg) -0.217 [-1.337; 0.904] -1.929* [-3.742; -0.116]
Fat free mass (kg) 0.780 [-0.212; 1.722] 0.473 [-0.897; 1.844]
Waist circumference (cm) -1.380 [-2.822; 0.061] 0.040 [-2.588; 2.668]
Waist-hip ratio 0.002 [-0.016; 0.021] 0.021 [-0.015; 0.057]
Systolic blood pressure (mmHg) -1.497 [-4.265; 1.272] -8.038* [0.014; -14.391]
Diastolic blood pressure (mmHg) -0.599 [-2.553; 1.355] -5.073** [-8.845; -1.301]
LDL cholesterol (mmol/l) -0.138 [-0.369; 0.093] -0.076 [-0.491; 0.339]
Resting heart rate (b/min) 2.540 [-0.865; 5.946] -1.995 [-8.277; 4.286]
Carotid intima-media thickness (mm)‡ 0.010 [-0.017; 0.036] 0.020 [-0.035; 0.075]
Glycated hemoglobin (%) -0.019 [-0.138; 0.101] -0.025 [-0.207; 0.157]
Data is presented as regression coefficients (β) and their corresponding 95% confidence intervals (CI)
CVD – cardiovascular disease; DM-2 – type 2 diabetes mellitus
Models were adjusted for gender and adult body weight * p < 0.05 ** p < 0.01
‡ also adjusted for systolic and diastolic blood pressurePage 5 of 9
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none of these associations were statistically significant.
Discussion
In this study, the associations between a polymorphism in
promoter region of the IGF-I gene, birth weight, (as a
measure of intra-uterine growth), and risk factors for CVD
and T2DM were investigated, in order to obtain more
insight into the genetic aspects of the fetal origins hypoth-
esis [1,5,6,30,31](The results of the present study demon-
strate that men who were carriers of one or two variant
allele(s) of the IGF-I gene had significantly lower birth
weights. However, this trend was not observed in women.
It is not clear, why this association was absent in women,
as no other study has reported gender differences in the
association between IGF-I genotype and birth weight
[13,32,33]. Therefore, the gender difference observed in
this study might be a result of chance
So far, results on the association between IGF-I genotype
and birth weight have been conflicting. Vaessen et al.
reported that absence of the wild type allele (192 bp)
resulted in a lower birth weight, but subjects who were
heterozygous for the wild type allele did not differ in birth
weight from the homozygous subjects [13]. Nevertheless,
Vos et al. [33], Frayling et al. [32] and Day et al [34] could
not confirm these findings. These conflicting results could
be due to differences in the population backgrounds, but
also to the way in which subjects were classified per geno-
type. In the present study, an alternative method was
used, in which the allele with 194 bp was also considered
as a wild type allele, based on the observations made by
Rietveld et al[24]. Subjects previously categorised as VC
were now categorised as WT (e.g. subjects with genotype
192 bp/194 bp, or 194 bp/194 bp). Therefore, the VC
group in other studies was actually heterogeneous, which
may explain discrepant observations. To investigate this
possible explanation, we investigated the characteristics of
the subjects who would have been categorised as VC
according to the traditional classification, and were now
categorised as WT (84 subjects). The men in this group
had a mean birth weight of 3.63 kg (± 0.51 kg), which is
comparable with the men who were categorised as WT in
both classification methods (3.64 ± 0.43 kg). The women
in this group had a mean birth weight of 3.44 kg (± 0.53
kg), which is exactly the same as the women classified as
WT in both methods. Besides this, the three groups were
also different with regard to the interaction between birth
weight and SBP and DBP in a way that the relationship
between birth weight and adult SBP and DBP was strong-
est and significant in the 'constant' VCs (β = -8.0 for SBP
and β = -5.1 for DBP), and weak and not significant in the
two other groups. These results suggest that the alternative
method used in the present paper discriminates better
between the genotypes with regard to the observed health
outcomes.
The results concerning risk factors for CVD and T2DM
showed an increased risk in the VC group solely for LDL
concentrations, all other risk factors did not differ
between WT and VC groups. That only one risk factor was
significantly different between the groups might be real or
a result of chance, since we tested several associations.
Moreover, the relationship between IGF-I genotype and
LDL concentrations disappeared after adjustment for BMI
and there were no differences in HDL concentrations (p =
0.255, data not shown). Several studies have shown that
lower IGF-I bio-activity is related to higher incidence of
atherosclerotic cardiovascular disease, higher carotid IMT
values, lower levels of HDL cholesterol, and impaired glu-
cose tolerance [5-7,35].(However, other studies have
failed to show these associations [36-38] Until now,
observations have thus been inconsistent, which may be
due to other factors that affect cardiovascular health,
insulin metabolism and serum IGF-I levels, such as nutri-
tion and endocrine factors. One should, however, realise
that the subjects of the present study were still rather
young (i.e. 36 years), and that a longer exposure to lower
IGF-I bioactivity might be necessary to induce unfavoura-
ble levels of risk factors for CVD and/or T2DM.
Another aim of the present study was to investigate
whether birth weight was associated with risk factors for
CVD and T2DM. This was found to be the case for FFM,
however this association decreased after adjustment for
body weight. When studying this association within ter-
tiles of BMI, it was found that only in the 2nd tertile the
relationship between birth weight and FFM was signifi-
cant (data not shown). Another significant association
was found between birth weight and for SBP, which is in
line with others and previously found in the
AGAHLS[39,40]. No other significant associations were
found, although the associations between birth weight
and adult LDL, FM and waist circumference were in the
expected (negative) directions [41-46] No associations
were found between birth weight and resting heart rate or
carotid IMT. This latter finding is in contrast with what has
been reported by Leeson et al. [47]. However, their study
focussed on an older population.
Birth weight is considered to be mainly dependent on the
intra-uterine environment, such as the availability of
nutrients and oxygen [30]. In the present population, the
IGF-I genotype could only explain 6% of the variance in
birth weight in men, and only 1% of the variance in birth
weight in women. The magnitude of the relationship
between birth weight and risk factors for CVD and T2DM,
however, seems to be dependent on genes (i.e. IGF-I pro-
moter polymorphism) (Table 4). This modification wasPage 6 of 9
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blood pressure. In the VC group, a 1 kg lower birth weight
was found to be related to an 8 mmHg increase in SBP,
which is much more than has been reported in the litera-
ture (2 to 3 mm Hg) [39]. The relationship between birth
weight and DBP was also stronger than was expected (as 1
kg lower birth weight was related to a 5 mmHg increase in
DBP). No other study has reported on interactions
between genes and birth weight in the relationship with
adult blood pressure, although IJzerman et al, in twins
studies, have shown that the association between birth
weight and blood pressure depends on genetic factors
[48,49] Interactions between birth weight and other genes
have been reported before, which might suggest that some
genotypes are more prone to adverse circumstances dur-
ing fetal growth, under the assumption that birth weight
is mainly dependent on the intra-uterine environment
[15-17] On the other hand, the observed interactions
between birth weight and IGF-I promoter polymorphism
genotype could be a result of a gene-gene interaction,
since birth weight is also determined by genes (other than
the IGF-I gene).
This study was conducted in 264 subjects only, which is
considered few in studies on genetic associations. This
might be a reason that we did not find significant associa-
tions between genotype and the risk factors. Subjects born
pre term were excluded, since gestational age may be
another factor associated with risk factors for CVD and
T2DM, but with another underlying mechanism [21]. We
reanalysed the data including subjects born pre term but
fulfilling the other inclusion criteria (N = 22), which
showed some different β 's (birth weight was now signifi-
cantly associated with FM, waist circumference (unad-
justed model) and with DBP pressure (adjusted model)).
However, the interaction between birth weight and IGF-I
genotype was the same, with strong associations between
birth weight and SBP and DBP in the VC (β = - 8.40 and β
= -5.67, respectively). Furthermore, despite the fact that
the AGAHLS is a longitudinal study, no data was available
on infant growth, nor reliable data on birth length was
available. If so, it was possible to study effects of IGF-I gen-
otype on infant growth or interactions with infant growth.
Conclusion
From this study, it is concluded that IGF-I promoter poly-
morphism genotype is related to birth weight in men
only, that this genotype is not associated with risk factors
for CVD and T2DM, and, most interestingly, that the IGF-
I promoter polymorphism genotype modifies the relation-
ship between birth weight and risk factors for CVD and
T2DM, especially for SBP and DBP.
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